Publication:
Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension

dc.contributor.authorNonlawan Chueamuangphanen_US
dc.contributor.authorJayanton Patumanonden_US
dc.contributor.authorWattana Wongtheptienen_US
dc.contributor.authorWeerasak Nawarawongen_US
dc.contributor.authorApichard Sukonthasarnen_US
dc.contributor.authorSuporn Chuncharuneeen_US
dc.contributor.authorChamaiporn Tawichasrien_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherThammasat Universityen_US
dc.contributor.otherChiang Rai Prachanukhro Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherClinical Epidemiology Societyen_US
dc.date.accessioned2018-11-09T02:34:53Z
dc.date.available2018-11-09T02:34:53Z
dc.date.issued2014-08-19en_US
dc.description.abstractObjective: The aim of the research reported here was to compare pulmonary artery systolic pressure (PASP) and 6-minute walk distance after 1 year of follow-up in hemoglobin E/β thalassemia (E/β-Thal) with pulmonary arterial hypertension (PAH) patients who received chronic blood transfusions versus those who received occasional transfusions. Methods: A nonrandomized clinical trial was conducted at the Hematological Outpatient Clinic of Chiang Rai Hospital, Thailand. All adult cases of E/β-Thal with PAH (defined as PASP >35 mmHg by Doppler echocardiography) were evaluated and followed for the next 12 months. The patients were classified into two groups by patient preference. Group 1 patients received chronic blood transfusions - one to two units of leukocyte-poor packed red cells every 2-4 weeks - over 1 year to maintain pre-transfusion hemoglobin levels of ≥7.0 g/dL. Group 2 patients received occasional transfusions over the course of 1 year, with more than 4 weeks between transfusions. All patients were treated with iron chelation when serum ferritin levels were > 1,000 μg/dL. PASP and the 6-minute walk distance were evaluated at baseline and at 6 and 12 months. Propensity score adjustment was used to control for confounding by indication and contraindication. Multivariable regression analysis was used to evaluate the effects of chronic blood transfusion. Results: There were 16 (53.3%) patients in Group 1 and 14 (46.7%) in Group 2. At 12 months, patients in Group 1 had a greater reduction in PASP than those in Group 1 (adjusted mean difference, -16.83; 95% confidence interval, -26.35 to -7.32; P=0.001). The 6-minute walk distance at 12 months in Group 1 patients was greater than that in Group 2 patients (adjusted mean difference, 46.55; 95% confidence interval, 18.08 to 75.02; P=0.001). Conclusion: This study found evidence that chronic blood transfusions may have beneficial effects in PAH in thalassemia patients over 1 year. © 2014 Chueamuangphan et al.en_US
dc.identifier.citationInternational Journal of General Medicine. Vol.7, (2014), 411-416en_US
dc.identifier.doi10.2147/IJGM.S66610en_US
dc.identifier.issn11787074en_US
dc.identifier.other2-s2.0-84907335967en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34213
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907335967&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleBenefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertensionen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84907335967&origin=inwarden_US

Files

Collections